Navigation Links
FDA Clears Abbott's i-STAT® 1 Wireless Point of Care Testing System
Date:3/29/2011

PRINCETON, N.J., March 29, 2011 /PRNewswire/ -- Abbott announced today it has received clearance from the U.S. Food and Drug Administration to begin marketing the i-STAT® 1 Wireless handheld, a new wireless version of the i-STAT® point of care testing system that is widely used in hospitals, emergency rooms and physicians' offices. The new i-STAT 1 Wireless handheld will allow real time transmission of diagnostic test results generated by i-STAT 1 directly from the patient bedside.

"With i-STAT 1 Wireless, caregivers are able to share critical test information electronically without leaving the patient's bedside," said Greg Arnsdorff, head of Abbott's point of care business. "By empowering nurses to stay at the bedside, the new i-STAT 1 Wireless supports a patient-focused approach to treatment, allowing for expedited decision making that helps minimize time to treatment."

The handheld analyzer can potentially save precious time by allowing caregivers to perform critical tests at the bedside and then transmit test results immediately so they can be reviewed by physicians anywhere they have access to electronic records.  Eliminating back-and-forth movement from the bedside to a desktop transmission terminal somewhere in the department gives staff the ability to better focus on the patient.

"With wireless, physicians can receive immediate test information in the electronic medical record, enabling them to act quickly when a patient's clinical status is rapidly changing," Arnsdorff said.

With the 10-minute i-STAT cardiac troponin test cartridge, for example, emergency department staffs can test, transmit and treat from the bedside. This helps health care providers maintain compliance with testing guidelines from the American College of Cardiology and American Heart Association, which call for a turnaround time of less than 60 minutes. By sharing these test results via a hospital's existing wireless network, caregivers have rapid access to information that can help determine if a patient is having a heart attack.

The i-STAT 1 Wireless handheld is certified for compatibility with existing wireless networks. It is also is compatible with point-of-care data management systems used with earlier versions of the i-STAT System.  The i-STAT 1 Wireless is the latest innovation from Abbott Point of Care, the U.S. market leader in bedside testing. The company offers the largest menu of diagnostic tests in a handheld platform and is used in nearly 2,000 hospitals in the U.S. and nearly 1,000 emergency departments.

About the i-STAT System

i-STAT 1 Wireless is a fully integrated system with a comprehensive test menu that enhances bedside testing workflow.  The i-STAT System can aide the physician in accelerating patient care decision making by quickly providing patient results that can be acted upon. Weighing just 18 ounces, the intuitive analyzer needs only two or three drops of blood to provide lab quality results.  Blood is added to disposable cartridges that contain test reagents; the cartridge is then inserted in the analyzer; and results are provided in minutes. In addition to cardiac markers, other i-STAT tests include chemistries, blood gases, electrolytes, and tests for lactate, hemoglobin, coagulation, and hematology.  In the U.S., the i-STAT System is used in nearly 2,000 hospitals and in nearly 1,000 emergency departments. Some 50,000 i-STAT analyzers are used worldwide and process about 100 million test cartridges a year. The system is relied on by clinicians in emergency departments, intensive care units, operating rooms, catheterization labs, outpatient clinics and physician offices. Technical support is available 24 hours a day. To learn more, visit www.abbottpointofcare.com.

About Abbott Point of Care

Abbott Point of Care, headquartered in Princeton, N.J., develops, manufactures and markets critical medical diagnostic and data management products for rapid blood analysis. The company's premier product is the i-STAT, a market-leading handheld blood analyzer capable of performing a panel of commonly ordered blood tests on two or three drops of blood at the patient's side.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's website at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears Palatin Technologies IND Filing to Commence Clinical Studies for Asthma
2. FDA Clears Test to Help Patients With Kidney Transplants
3. FDA Clears First Diagnostic Radiology Application for Mobile Devices
4. FDA Clears GeNO LLCs Investigational New Drug Application for Clinical Trials With Its NITROSYL™ Inhaled Nitric Oxide System
5. FDA Clears Volpara™ Breast Imaging Software for Automatic Calculation of Volumetric Breast Density
6. FDA Clears Cymbalta to Treat Chronic Musculoskeletal Pain
7. FDA Clears Software Upgrade for Fenwal Plasma-Collection System
8. FDA Clears AirStrip RPM for CRITICAL CARE & CARDIOLOGY Remote Patient Monitoring Solutions
9. FDA Clears Xlumenas NAVIX(TM) Access Device
10. FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni
11. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer ... prospects of the market globally. The stakeholders of ... the manufacture and commercialization of various mass spectrometer ... planning to enter this market. This report comprises ...
(Date:2/21/2017)... -- Luminex Corporation (NASDAQ: LMNX ) (the "Company") today ... of a quarterly cash dividend to its shareholders, the first ... payable on April 14, 2017 to shareholders of record as ... The board of directors intends for the Company ... holders of its common stock, representing a planned annual dividend ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Robins ... Clinic in Durant, Oklahoma, on Feb. 21. , The celebration began with a ... members, clinic employees, the construction team and tribal leadership. , Choctaw Nation ...
(Date:2/21/2017)... ... ... Doctors on Liens has announced the addition of Mendonca Spine Care Center ... network of doctors in Central and Northern California. Dr. Mendonca specializes in personal injury ... pain, neck pain, hip and knee pain, and headaches. Specializing in non-surgical, spinal ...
(Date:2/21/2017)... ... February 21, 2017 , ... Ray Insurance Agencies, a Dallas area firm providing ... is embarking on a six month charity event aimed at raising local support and ... is one of the deadliest diseases in America; more than 7.5 million people die ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... announced the further expansion of its eHealth App xChange™, providing clinical researchers ... of Bioclinica’s extensive and growing eHealth platform. Applications that enable patient-centered clinical ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... with over 50,000 participants. The connected care demonstration spanned multiple health information ... National Coordinator, roughly 30% of providers have no Health Information Exchange outside of ...
Breaking Medicine News(10 mins):